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ABSTRACT
The infection of normal mouse mammary EF43 cells by a retroviral
vector carrying either Fgf-3 (EF43.Fgf-3) or Fgf-4 (EF43.Fgf-4) cDNA
resulted in the transformation of cells displaying different tumorigenic
potentials in nude mice (A. Hajitou and I'-M. Calberg-Bacq, Int. J.
Cancer, 63: 702-709, 1995). EF43.Fgf-4 produced rapidly developing
tumors at all sites of inoculation, whereas EF43.Fgf-3 produced slowly
growing tumors only in the mammary fat pad. Cells infected with the
vector carrying the selection gene alone (EF43.C) were not tumorigenic.
The angiogenic properties of these cells were tested in an in vitro angio-
genesis model using human umbilical vein endothelial cells (HUVECs)
cultured at the surface of a type I collagen gel and their capacity to form
tube-like structures on invasion of the gel. Only the conditioned medium
(CM) of EF43.Fgf-4 induced an angiogenic morphotype in HUVECs. In
parallel, the mRNA expression of matrix metalloproteinase 1 and c-ETS-1
was increased in the HUVECs displaying a differentiated phenotype,
whereas the tissue inhibitor of matrix metalloproteinase 1 mRNA level
was decreased. Recombinant human fibroblast growth factor 4 (FGF-4)
did not induce an angiogenic phenotype in HUVECs by itself. By Western
blot analysis, a high expression of vascular endothelial growth factor
(VEGF) was detected in the EF43.Fgf-4 CM. This result was confirmed by
Northern blot analysis of total RNA extracted from the three cell types;
the steady-state level of VEGF mRNA was low and equivalent in EF43.C
and EF43.Fgf-3, whereas it was strongly increased in EF43.Fgf-4. Cul-
turing EF43 cells carrying only the selection gene with increasing concen
trations of recombinant human FGF-4 resulted in a dose-dependent stim
ulation of VEGF. The induction of the angiogenic morphotype and the
parallel modulations of the biosynthetic phenotype in HUVECs were
completely suppressed by adding a neutralizing antibody directed against
VEGF to EF43.Fgf-4 CM. Furthermore, inhibition of protein kinase C by
bisindoylmaleimide suppressed the angiogenic phenotype induced by the
CM of EV43.Fgf-4. Our results point to an indirect angiogenic activity of
FGF-4 through the autocrine induction of VEGF secretion by EÂ¥43.Fgf-4
cells, an original signaling pathway that might be significant in tumor
progression and metastasis.
INTRODUCTION
FGFs3 form a family of structurally related heparin-binding
polypeptides encoded by at least 14 different genes (1-3) among
which products FGF-1 to FGF-9 have been characterized (4-6).
Unlike FGF-1. FGF-2, and FGF-9. which lack a signal peptide, the
other FGFs are secreted. The FGFs and their transmembrane receptors
are essential during development (reviewed in Ref. 6), and the ex
pression of each member of the family and its receptors is spatiotem-
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porally and tightly regulated. Except for FGF-1 and FGF-2. which are
ubiquitous, and FGF-7, which is present in various epithelia, the other
FGFs are not produced or very weakly produced in normal adult
tissues. When ectopically expressed, they may be oncogenic. Fgf-4,
Fgf-5, and Fgf-6 were originally isolated as genes able to transform
NIH3T3 cells in culture (7). Fgf-3 has been identified as a main target
of mouse mammary tumor virus and is involved in mouse mammary
tumorigenesis (8). Fgf-4 is also activated by proviral insertion in
mouse mammary tumors (9), although much less frequently than
Fgf-3 (10). Fgf-4 expression has been associated with progression
toward a metastatic phenotype in mouse mammary carcinogenesis
(11). There is a strong selection for the activation of these two genes
in cooperation with Wnt-l oncogene expression in the induction of
mouse mammary tumors (12).
In a previous work, we infected normal mouse mammary EF43
cells (13) recently identified as myoepithelial cells4 with retroviral
vectors carrying either Fgf-3 (EF43.Fgf-3) or Fgf-4 (EF43.Fgf-4) or
the selection gene alone as control (EF43.C; Ref. 14). The parental
EF43 as well as the EF43.C cells were not tumorigenic when inocu
lated in nude mice. By contrast, the EF43.Fgf-4 cells induced rapidly
developing and aggressive tumors, whatever the site of injection. The
EF43.Fgf-3 cells produced slowly developing tumors after a lag
period of quiescence, but only after injection in the mammary fat pad.
In vivo, the switch from a quiescent tumor to an invasive neoplasm
is accompanied by neovascularization. or angiogenesis, a process
essential for tumor expansion (15, 16). The rapid development of the
EF43./rÂ£/-4-induced tumors was evocative of a sustained growth,
probably through a neovascularization process. In this work, we
analyze the angiogenic capacities of EF43 cells producing either
FGF-3 or FGF-4 by testing the medium conditioned by these cells in
culture. The in vitro angiogenesis model used HUVECs and their
capacity to invade a type I collagen gel and to form pseudocapillary
structures on angiogenic stimulation (17, 18). Our results demonstrate
an indirect angiogenic activity through the autocrine induction of
VEGF in EF43.Fgf-4 but not in Ef43.Fgf-3 cells.
MATERIALS AND METHODS
Cell Cultures and CM. HUVECs were isolated according to Jaffe et ni.
(19), as described previously (20). The cells were cultured on gelatin-coated
tissue culture dishes in RPMI 1640 (Lite Technologies. Inc., Grand Island,
NY) supplemented with 5% HDS. 5% FCS (Life Technologies. Inc.), 20 /Â¿g/ml
endothelial cell growth factor (Boehringer Mannheim, Mannheim Germany).
50 fj.g/ml heparin, 10 mm HEPES, penicillin (100 units/ml), and streptomycin
(100 fig/ml) and used at passage 2. The endothelial origin of the cells was
assessed as described previously (20). Endothelial cell growth factor and
heparin supplementation was suppressed when performing the experiments.
Mouse mammary cells were derived from the EF43 cell line (13) by
infection with retroviral vectors carrying Fgf-3 (EF43.Fgf-3). Fgf-4 (EF43.Fgf-
4), or the empty vector as control (EF43.C). as described previously (14). The
cells were cultured in DMEM (Life Technologies. Inc.) containing 10% FCS,
5 ng/ml mouse EOF (Sigma, Deisenhofen. Germany), 1 fig/ml bovine insulin
(Boehringer Mannheim), penicillin (100 units/ml), and streptomycin (100
Hg/ml).
4 A. Hajitou and C-M. Calberg-Bacq. FGF-3 and FGF-4 elicit distinct oncogenic
properties in mouse mammary myoepithelial cells, submitted for publication.
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For preparing CM, cultures of the three infected cell types were seeded at
specific cell densities to take into account the growth rate of each cell type to
obtain a similar number of cells in the dish at the time of CM collection. The
cultures were washed three times with serum-free RPMI 1640 with a 2-h
incubation for the last wash and then incubated in the same medium (6 ml:
5 X IO6 cells). The CM was collected after 24 h, centrifuged to remove cell
debris, passed through a 0.22-/nm tiller, and stored at 4Â°C.
In Vitro Angiogenic Assay. The in vitro angiogenic assay based on the
model of Montesano and Orci (17) was essentially performed as described
previously (18). Briefly. HUVECs suspended in 5% FCS. 5% HDS. and 90%
RPMI 1640 were seeded on a 0.4-mm-thick collagen gel (6 x IO4 cells/cm2)
and allowed to attach and spread for 3 h. The gel was made of RPMI 1640
containing 1 mg/ml purified type I collagen and was allowed to polymerize for
10 min at 37Â°C(20). After spreading of the cells, the medium was replaced by
a mixture containing 90% CM, 5% FCS. and 5% HDS and was renewed daily.
In some assays, a blocking polyclonal antibody directed against the rh 165-
amino acid form of VEGF (rhVEGFl65; Chemicon, Temecula, Ã‡A;AB1442)
was added to the CM of EF43./r#/'-4 at 10 /xg/ml and preincubated for 1 h at
room temperature before renewal of the medium. Rabbit IgG directed toward
an irrelevant antigen at the same concentration was used as control. When
needed, rhFGF-2 (Boehringer Mannheim), rhFGF-4 (ICN Pharmaceuticals,
Costa Mesa, CA). or rhVEGFl6, (Sigma) was added to the RPMI 1640.
HistolÃ³gica! Analysis. HUVECs cultured on a collagen gel for 8 days in
the presence of EF-43.Fgf-4 CM as described above were fixed with 3%
paraformaldehyde in PBS for 2 h, washed overnight in PBS supplemented with
6.8% sucrose, dehydrated with acetone, and embedded in methacrylate, with
all steps being carried out at 4Â°C.Serial sections of 2 /j.m were stained with
propidium blue.
Western Blot Analysis of VEGF. The analysis was performed on 1 ml of
CM dialyzed overnight against 100 ml of 200 mM ammonium acetate, lyoph-
ilized, and electrophoresed under nonreducing conditions on a 15% SDS-
polyacrylamide gel according to the technique of Laemmli (21). Western
blotting was performed as described by Towbin et al. (22) using a polyclonal
antibody antirecombinant human VEGF165 (Chemicon; AB1442) and. as
secondary antibody, peroxidase-conjugated swine antirabbit IgG (Dako,
Copenhagen. Denmark: P0217). Peroxidase was revealed by the enhanced
chemiluminescence assay (Amersham Corp.).
Western Blot Analysis of FGF-4. The analysis was performed on 5 ml of
CM partially purified on heparin-sepharose as described by Souttou et al. (23).
Western blotting was performed as described previously using a rabbit anti-
FGF-4 generously provided by Dr. C. Basilico (New York University School
of Medicine, New York. NY).
Northern Blot Analysis. Total RNA was purified according to Chirgwin cf
al. (24) with slight modifications, as described previously (25). When required,
the collagen gel was digested by incubation with O.I ml of 1% bacterial
collagenase (Sigma, C-9891) in RPMI 1640 for 10 min at 37Â°C,and the cells
were harvested by cemrifugation at 550 x g for 5 min. Northern blot analysis
was performed as described previously (25). Human probes were insert frag
ments of plasmids Gem 3collK4 for MMP1 (26), pTIMP for TIMP-1 (27),
Gem-ÃŸ-actin for /3-actin, pH3a for MMP2 (28). pSS38 for TIMP2 (29). and
ETS-1 for c-ETS-1 (30). An end-labeled oligonucleotide specific for human
and mouse 28S recombinant RNA (Promega) was used to monitor the amount
of loaded RNA. The probe for murine VEGF was a complete VEGFlh4 cDNA
generously provided by P. D'Amore (Laboratory for Surgical Research. Chil
dren's Hospital. Boston. MA). All probes were labeled using |3;!P]dATP and
['2P]dCTP (ICN Pharmaceuticals Inc.; 3000 Ci/mmol) and a random-primed
DNA labeling kit (Boehringer Mannheim). Prehybridization was performed in
50% formamide. 2 X SSC. 5 x Denhardt's solution. 0.1% SDS, and 5%
dextran sulfate. Hybridization was performed for 16 h in the same mix at 42Â°C
for all the probes except for MMPI. which required 52Â°C.The signal inten
sities were measured by laser scanning densitometry (Ultroscan LKB, Uppsala.
Sweden).
RESULTS
Induction of an Angiogenic Phenotype in HUVECs by CM from
EÂ¥43.Fgf-4. HUVECs plated on a collagen gel were cultured in
presence of CM from the three types of infected mouse mammary
cells to examine whether soluble factors produced by cells presenting
different tumorigenic potentials in vivo could affect the behavior of
endothelial cells in the in vitro angiogenic assay.
In control RPMI 1640, HUVECs seeded at the surface of a type I
collagen gel attached, spread, and proliferated to form a monolayer
presenting, at confluence, a typical cobblestone-like morphology (Fig.
la). In the presence of CM from EF43.C (Fig. \b) or from EF43.Fgf-3
(Fig. le), the HUVECs maintained their typical monolayer pattern for
up to 14 days. They remained superficial and never invaded the gel.
In the presence of CM from EF43.Fgf-4. the morphology of the
culture was disturbed by a progressive loss of the uniform cobble
stone-like pattern and by the acquisition by the cells of a spindle-
shape morphology (Fig. \d). After 6-9 days of culture in daily
renewed CM of EF43.Fgf-4, an appreciable number of HUVECs
Fig. 1. Phase-contrast micrographs of HUVECs cul
tured on a collagen gel for 8 days with unconditioned
medium (Â«)and with medium conditioned by EF43.C
(b). by EF43.Fgf-3 (c). and by EF43.Fgf-4 (di e. pho
tograph of the same field as in ti but focused on a
branching tube-like structure 20 firn under the HUVEC
monolayer. Bar. 25 urn.
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Fig. 2. Transverse section of HUVECs cultured on a collagen gel for 8 days with
medium conditioned by EF43./rÂ£/W shows the monolayer of cells at the surface of the
collagen gel (a), and cells within the collagen gel associated into tube-like structures and
delineated a lumen (In. Bar. 4 \un.
migrated within the collagen gel and organized into elongated and
branched structures as observed by phase-contrast (Fig. 1, d and e).
HistolÃ³gica! examination (Fig. 2) revealed a continuous monolayer of
HUVECs at the top of the collagen gel, and HUVECs associated into
tube-like structures and delineated a lumen inside of the gel.
Modulation of the HUVEC Phenotype by the CM of
EF43.Fgf-4. The phenotype of the HUVECs was evaluated by meas
uring the steady-state level of mRNA coding for proteolytic enzymes
involved in the extracellular matrix degradation (MMP1 and MMP2).
their physiological inhibitors (TIMP1 and TIMP2). and ETS-1. a
recognized transcription factor playing a role in in vitro and in vivo
angiogenesis (31, 32). Total RNA was extracted from HUVECs
cultured for 8 days in the presence of CM from the three infected cell
types. HUVECs maintained in the CM of EF43.C did not differ from
the cells in contact with the CM of EF43./â€¢#/-.?in the expression of
MMP1. TIMP1. or c-ETS-1 (Fig. 3. Lanes I and 2). The angiogenic
phenotype induced by CM of EF43.Fg/-4 was associated with an
increased expression of the mRNA coding for MMP1 (Fig. 3, Lane 3)
and a decreased expression of the mRNA coding for its physiological
inhibitor. TIMP1 (Fig. 3, Lane 3), resulting in a MMP1:TIMPI
mRNA ratio increased by a factor of 20. A significant increase in
c-ETS-1 mRNA expression was also observed in this condition (Fig.
3, Lane 3), whereas the mRNA level for MMP2. TIMP2. and ÃŸ-actin,
which were all constitutively expressed, was not significantly modu
lated in any of the culture conditions (Fig. 3). This pattern of expres
sion of mRNA represents additional support for the differentiated
phenotype of the HUVECs under the activity of CM of EF43.F<>f-4.
Induction of VEGF Expression by FGF-4. rhFGF-4 added to
HUVECs at a concentration as high as 50 ng/ml did not induce any
morphological change in the HUVECs cultured on a collagen gel
(data not shown), in agreement with its lack of angiogenic properties
as demonstrated in vivo and in vitro by Jouanneau et al. (33). This
observation suggested that another factor or factors present in the CM
ofEF43.Fgf-4 might be responsible for the angiogenic properties. We
tested rhFGF-2, one of the first described angiogenic factors. It was
less efficient in the induction of tube-like structures in our experi
mental model, even at a concentration as high as 20 ng/ml. whereas
rhVEGFu,s proved to be a potent stimulator (Fig. 4).
Western blot analysis revealed the actual presence of VEGF in the
CM of EF43.Fgf-4 (Fig. 5A). whereas in the CM of EF43.C and
EF43.FS/-.ÃŽ,it was nearly undetectable for a similar amount of pro
teins loaded in each lane, as shown by Coomassie Blue staining of
samples run in parallel (Fig. 5B). The VEGF detected in the
EF43.Ff>f-4 CM is most likely the 164-amino acid murine form,
because it migrates at the same position as rhVEGF,,,v This result
was confirmed by measuring the steady-state level of VEGF]64
Fig. 3. Northern blol analysis of mRNA steady-
state levels. Total RNA was extracted from HU
VECs cultured on a collagen gel for 8 days with
medium conditioned by EF43.C (Lanes /),
EF4i.Fgf-3 (Lanes 2), and EF43.Fgf-4 (Lanes 3).
The 28S rRNA was hybridized on the same mem
branes with a specific oligonucleotide. as detailed in
"Materials and Methods." to normalize the amount
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Fig. 4. Phase-contrast micrographs of HUVECs cultured on a collagen gel for 6 days
with control medium (Â«)or with 20 ng/ml rhVP.OF|ft; (hi. c. photograph of the same field
as in b but focused on a branching tube-like structure 15 firn under the HUVEC
monolayer. Bar, 25 [j.m.
antibody at the same IgG concentration did not affect the induction of
tube-like structures by the CM of EF-43.Fgf-4 (Fig. 8i/).
The phenotypic changes induced by the CM of EF43.Fgf-4, i.e., an
increased level of MMP1 and c-ETS-1 mRNAs and the reduced
expression of TIMP1 mRNA, were suppressed by the neutrali/ing
anti-VEGF antibody, whereas the irrelevant antibody had no effect
(Fig. 9).
The EF43.Fg/"-4-induced Angiogenic Morphotype Is Mediated
through a PKC-dependent Pathway. BIM added to the CM of
EF43.Ff>f-4 completely suppressed the formation of tube-like struc
tures. In the presence of this PKC inhibitor, the monolayer pattern was
maintained for up to 14 days, and no cell was seen invading the
collagen gel (Fig. 10/4). In spite of the abolition of the angiogenic
morphotype by BIM, the accompanying increased mRNA steady-state
level of both MMP1 and c-ETS-1 was not suppressed, whereas the
reduced expression of TIMP1 reverted to a high level (Fig. l()ÃŸ).This
suggested that induction of the angiogenic morphotype and up-regu-
lation of MMP1 and c-ETS-1 are mediated through distinct signaling
pathways. By contrast, down-regulation of TIMP1 introduced by the
CM of EF43.Fgf-4 is PKC dependent.
DISCUSSION
The induction and maintenance of tumor blood vessel supply are
essential requirements for the growth of solid cancers and their








Fig. 5. A. Western blot analysis of medium conditioned by EF43.C (Lanes 2),
EF41.Fgf-3 (Lanes 3). and EF43.Fgf-4 (Lanes â€¢¿/).As a positive control. 20 ng of
rhVEGF|M were loaded in Ltines I. B. Coomassie Blue staining of a SPS-PA(Ã¬I: run in
parallel and loaded with the same samples as in A.
mRNA in the three cell types by Northern blot analysis. Its level was
low in EF43.C and in EF43.Fgf-3 and was strongly enhanced in
EF43.F<>f-4(Fig. 6). Moreover, culturing EF43.C in the presence of
increasing concentrations of rhFGF-4 for 48 h and then conditioning
the medium for 24 h as described in "Materials and Methods" resulted
in a dose-dependent induction of VEGF^ secretion already detect
able by Western blot analysis in CM supplemented by 10 ng/ml
rhFGF-4 (Fig. 7).
The Angiogenic Phenotype of HUVECs Induced by EF-
43.Fgf-4 Is Mediated by VEGF. Preincubation of the CM of EF-
43.Fgf-4 with a VEGF neutralizing antibody for l h abolished the
induction of the angiogenic morphotype in the HUVECs. Under these
conditions, cells multiplied until confluence but did not invade the
collagen gel and kept the cobblestone-like morphology throughout the







Fig. 6. Northern blot analysis of mRNA steady-state levels for mouse VEGF,M. Total
RNA was extracted from EF43.C (Lane /). EF4i.Faf-3 (Lane 2), and EF43.Fgf-4 (Lane
3}. The 28S rRNA was hybridized on the same membrane with a specific oligonuclcotide
as detailed in "Materials and Methods" and was used to normalise the amount of total
RNA loaded in each lane.
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Fig. 7. A, Western blot analysis of medium con
ditioned by EF43.C cultured without (Lanes 3} or
with \0 (Lanes 4). 20 (Lanes 5}. 50 (Lanes 6) or 100
(Lanes 7) ng/ml rhFGF-4. rhVEGF,,,, (20 ng/mll
was loaded in Lanes 1. and 100 ng of rhFGF-4 were
loaded in Lanes 2. B, Coomassie Blue staining of a






tion of angiogenesis-promoting growth factors by tumor cells (15). In
this work, the angiogenic potential of three mouse mammary cell
types that express variable tumorigenic phenotypes was investigated.
The cells (EF43) were derived from a clonal outgrowth in a mammary
Fig. 8. Phase-contrast micrographs of HUVECs cultured on a collagen gel for 8 days
with medium conditioned by EF4ÃŒ.Fgf-4in the presence of a control antibody (a). In b,
HUVECs were cultured in the same conditioned medium but in the presence of a
neutrali/ing anti-VEGF antibody. Bar. 25 /im.
gland culture from a y-irradiated BALB/c mouse (34) and were
recently shown to be of myoepithelial origin.4 As demonstrated in a
previous work (14), the control EF43 cells (EF43.C) infected by the
retroviral vector carrying only the selection gene are not tumorigenic.
The EF43 cells carrying Fgf-3 (EF43.Fgf-3) produce tumors devel
oping with a significant delay and only when implanted in the mam
mary fat pad, whereas the EF43 cells carrying Fgf-4 (EF43.Fgf-4)
give rise to rapidly growing tumors independently of the inoculation
site.
The overexpression of growth factors is known to confer a tumor
igenic potential to normal cells (7, 35, 36). The introduction of Fgf-4
in various cell types of murine or human origin results in a high
production of this growth factor, which clearly modifies their in vitro
and in vivo phenotype and induces several significant hallmarks of
transformation including morphological changes, proliferation in low
serum conditions, growth in soft agar. and formation of solid tumors
(23, 33, 35, 37). Such modifications of the in vitro and in vivo
phenotype are expressed by EF43 cells carrying Fgf-4, indicating that
they possess functional receptors allowing an autocrine regulation
pathway and comply with the observation of Talarico and Basilico
(38) that secretion is a prerequisite for Fgf-4-Ã¬nducedtransformation.
Our initial observation that the CM of the FGF-4-producing cells
induced an angiogenic phenotype in HUVECs was consistent with the
potent oncogenic activity of Fgf-4 (7, 23, 39, 40). However, the
addition of rhFGF-4 to HUVECs up to 50 ng/ml failed to induce an
angiogenic phenotype in the HUVECs, a result in agreement with
Jouanneau et al. (33), who showed that biologically active FGF-4
secreted by rat bladder carcinoma cells or recombinant FGF-4 did not
induce tubulogenesis by bovine microvascular endothelial cells using
an in vitro angiogenesis model similar to ours. rhFGF-4 has been
shown to induce neovascularization in vivo in the chick chorioallan-
toic membrane and in rat cornea assays (39). In these in vivo assays,
however, it is not known if the growth factor is acting directly or
indirectly by inducing the expression of angiogenic factors. The in
vitro mitogenic effect of FGF-4 on endothelial cells reported by
Miyagawa et al. (41) and Delli Bovi et al. (42) addresses only a part
of the complex angiogenesis process. The test used in the present
study does not involve endothelial cell proliferation (17, 18). It
mimicks selected events of the angiogenic process, i.e., migration of
endothelial cells into the perivascular stroma, cellular alignment, and
5594
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c-ETS-1
MMP1 â€¢¿
In parallel to the morphogenetic events resulting in the formation of
tube-like structures, the EF43.Fgf-4 CM induced in HUVECs an
increased expression of the mRNA coding for MMP1 and c-ETS-1
and a decreased expression of the mRNA coding for TIMP1. An





Fig. 9. Northern blot analysis of mRNA steady-state levels. Tolal RNA was extracted
from HUVECs cultured on a collagen gel for 8 days with medium conditioned by
EF43.Fgf-3 (Lane /) or EF43.Fg/W (Limes 2-4) in the presence of a control antibody
(Lane 3) or a neutralizing anti-VEGF antibody (Lane 41. The 28S rRNA was hybridized
on the same membrane with a specific oligonucleotide as detailed in "Materials and
Methods" and was used to normalize Ihe amount of total RNA loaded in each lane.
the generation of a patent lumen, a morphogenic process that is not
induced directly by FGF-4. These results suggested that another factor
present in the CM of EF43.Fgf-4 was responsible for its angiogenic
activity. The weak morphogenetic effect of FGF-2 in our in vitro
angiogenesis assay as compared with recombinant VEGF and the
extensive vascularization of FGF-4-induced tumors suggested that
VEGF might be a good candidate. A number of growth factors and
cytokines as EGF, FGF-7, platelet-derived growth factor-BB. tumor
necrosis factor a, transforming growth factor ÃŸ,or interleukin 1/3
have been reported to induce the expression of VEGF in a variety of
cultured cells (43). Moreover, it was recently reported that the acti
vation of oncogenic H-ras also stimulated the expression of VEGF
mRNA (44). In addition, the correlation between the up-regulation of
VEGF and malignant progression in a mouse skin carcinogenesis
model (45), the association of VEGF expression with high microves-
sel density in primary breast carcinomas, and poor prognosis due to
early relapse (46) are further elements supporting the relationship
between VEGF in EF43.Fgf-4 cells and their aggressive phenotype.
Western blot analysis of CM collected from the three cell types
demonstrated that VEGF|M was only secreted by EF43.Fgf-4 cells,
whereas Northern blot analysis revealed that this overexpression was
at least partially controlled at a pretranslational level through an
increased steady-state level of its mRNA. These results suggested that
VEGF]64 expression was induced in response to FGF-4 production
through an autocrine loop in EF-43.Fgf-4 cells. The up-regulated
expression of VEGF,,^, by adding recombinant FGF-4 to EF-43.C,
the control cells carrying only the selection gene, is a direct argument
supporting this mechanism. Cooperation between VEGF and another
growth factor like FGF-2 (47) cannot be ruled out. However, the
inhibition of tube-like structures formation and the suppression of
associated phenotypic changes by a VEGF-neutralizing antibody
clearly demonstrate that VEGF is the main factor responsible for the
angiogenic events triggered by the EF43.Fgf-4 cells. In contrast,
FGF-3 overexpression in EF-43.Ff>f-3 cells reported by Hajitou and
Calberg-Bacq (14) did not up-regulate VEGF, suggesting that this
characteristic is not a common feature of all members of the FGF
family. This could be related to the retardation of FGF-3 in the Golgi,
even if the production of this protein was sufficient to confer
EF43.Fgf-3 cells with a tumorigenic phenotype (14). The lack of
induction of an angiogenic phenotype in HUVECs by EF-43.Fgf-3







Fig. 10. A, phase-contrast micrographs of HUVECs cultured on a collagen gel tor 8
days with medium conditioned by EF43.Fjc/'-4. In a and c. the microscope is focused on
the gel. /', photograph of the same field as in a but focused on a branching tube-like
structure 20 jim under the HUVEC monolayer. In r, HUVECs were cultured in presence
of 2.5 fig/ml BIM. Bar, 50 Â¿un.B, Northern blot analysis of total RNA extracted from
HUVECs cultured in the presence of CM of EF43.C (Urne I) or in the presence of CM
of EF43./-K/W (Lanes 2 and .?) in the absence (Lane 2) or presence (Lane 3) of 2.5 fig/ml
BIM. The 28S rRNA was hybridized on the same membrane with a specific oligonucleo
tide as detailed in "Materials and Methods" and was used to normali/e the amount of total
RNA loaded in each lane.
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by VEGF has been described previously (32, 48). Degradation of type
I collagen was indeed considered necessary for angiogenesis in vitro
(49). and c-ETS-1. a known transactivating factor of MMP1. could
participate in the up-regulation of this enzyme in HUVECs. EOF and
FGF-2 were also reported to induce protease expression in endothelial
cells through an overexpression of c-ETS-1 (32). This overexpression,
mediated through a paracrine activity in our most tumorigenic cells,
agrees with the observed correlation between peritumoral (fibroblasts
and endothelial cells) expression of c-ETS-1 and tumor invasiveness
(SO). It has to be noted that the pathways leading to tubulogenesis and
overexpression of the MMP1 and c-ETS-1 genes are at least partly
divergent, because only the morphogenic events are inhibited by a
PK.C inhibitor. VEGF has indeed been reported to activate PKC-
dependent phospholipase D, which could regulate cell migration in
volved in angiogenesis (51). A regulation of TIMP1 in HUVECs by
VEGF has not been reported. The CM of EF-43.C and EF43.Fgf-3
induced an increase of TIMP1 mRNA in HUVECs as compared to
unconditioned medium (data not shown). This stimulation was not
observed with the CM of EF43.Fgf-4. suggesting that VEGF is able to
suppress this overexpression to the level of constitutive expression.
The lack of modulation of MMP2 and TIMP2 mRNA steady-state
levels in HUVECs agrees with similar observations of the effect of
VEGF by Unemori et al. (48).
FGF-4 has been reported to induce the expression of 21 genes in
NIH3T3 cells (52). Even if most of the induced genes are prolif
eration specific, the authors did not find an induction of VEGF.
suggesting that the autocrine loop observed in our study could be
cell-type specific. This hypothesis is also supported by the diver
gent results reported in the literature. F^/'-4-transfected human
breast MCF7 cells produce tumors described as abundantly vascu-
larized (35). as does the high producer clone HH9 isolated from
Ftf/W-transfected HBL 100 (23). The tumors produced by our
EF43./rÂ£/'-4cells are also largely vascularized (data not shown). On
the other hand, the rat bladder carcinoma cell line NBT-II. trans-
fected with Fgj'-l coupled to a signal peptide forms rapidly grow
ing carcinomas that are highly vasculari/.ed. whereas the same cells
transfected by Fgf-4 and producing a biologically active form of
FGF-4 induce slowly growing tumors as untransfected cells (33).
The failure of some F,i;/'-4-transfected cells to display increased
angiogenesis might be related to the panel of receptors expressed
at the cell surface (53). It could also depend on the developmental
origin of the cells, the mammary gland for EF43. MCF7. and HBL
100 and the urinary bladder for the nonresponsive NBT-II. Addi
tional investigations are needed to define these determinants.
In a recent review, D'Amore and Shima (16) stated that tumor
angiogenesis could be an example of a physiological process initiated
by tumor growth-induced hypoxia. Our observations demonstrating
that FGF-4 up-regulates VEGF expression in well-oxygenated in vitro
conditions does not favor that proposition and would support the
alternate hypothesis of the same authors stating that an event written
in the genetic program of the tumor cells is the leading cause of the
process. The autocrine loop of FGF-4 and the resulting induction of
VEGF might represent that signaling pathway operating in tumor
progression and metastasis.
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